Skip to main content
. Author manuscript; available in PMC: 2022 May 4.
Published in final edited form as: Bone Marrow Transplant. 2017 Jan 9;52(5):759–761. doi: 10.1038/bmt.2016.346

Figure 1.

Figure 1.

Evidence of graft versus host disease post-nivolumab inhibition. Nivolumab 0.5mg/kg was administered on day 0 (solid arrow) and 1mg/kg on day 14 (solid arrow). Liver enzymes, ALT (red) and AST (green) rise following nivolumab administration. Notable elevations of CD8 (blue) and CD4 (black) also occurred following administration of nivolumab. Steroid (i.e. methylprednisolone) doses are shown. Basiliximab and infliximab (B/I) were administered with subsequent basiliximab (B) doses given.